The dual analgesic Therapeutics, an immunotherapy company in the clinical trials phase, today reports positive results in a clinical trial in Allocetra for the treatment of corona patients in a difficult and critical condition. The report comes after unofficial reports were published in the media last night about the experiment and after a cessation of trading in the stock was announced this morning.
The clinical trial included 5 corona patients, 3 of them in critical condition and 2 more in critical condition. All five patients fully recovered from the previous condition and were discharged from the hospital after an average of 5.5 days (patients in critical condition) and 8.5 days (patients in critical condition) after starting treatment with Allocetra. All patients received a negative coronary test result at the time of discharge. No serious side effects were reported with Allocetra treatment and were considered tolerable.
The company notes that treatments such as plasma-based antibodies are usually given to patients in moderate condition. Allocetra, if approved, can potentially cover the gap, and treat patients in a critical / critical condition.
Based on the positive results from the first five corona patients in severe / critical condition, along with positive safety and efficacy results using Allocetra in 10 sepsis patients in a previous trial, the company decided to divert more patients to an extended phase 2 trial in severe / critical, early corona patients. As far as possible, after regulatory approval.
Prof. Vernon van Heerden, Director of the Intensive Care Unit at Hadassah Hospital in Israel and Principal Investigator of the Corona and Sepsis Experiments, stated that “To date, we have treated 15 patients with Allocetra at the hospital, 10 of them with sepsis and 5 with “Corona is in a difficult or critical condition. Based on the preliminary results that have shown safety and an indication of the effectiveness of Allocetra in patients with these complications, the Anallox Allocetra product has the potential to help Corona patients in a critical / critical condition.”
Prof. Dror Mevorach, Medical Director of Analybex, added: “The results of the treatment of Allocetra in corona patients in a critical and critical condition reflect a unique opportunity for Analybex to contribute to the efforts to combat the ongoing global epidemic of Corona. The initial positive results observed in Allocet patients treated with Allocet Corona is in a difficult and critical situation. “
All corona trials are planned to be conducted separately from the planned Phase IIb Allocetra trial to treat systemic collapse due to sepsis. The above experiment will be controlled and randomized, which is expected to begin by the fourth quarter of 2020.
*The article has been translated based on the content of Source link by https://www.sponser.co.il/Article.aspx?ArticleId=102090
. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!